Category: Wright Medical Group Inc.
Wright Medical gains 510(k) clearance from the FDA for its Salvation external fixation device for foot and ankle surgeries.
A pair of high-volume orthopedic surgeons say they're skeptical of so-called 'repless' sales models such as Smith & Nephew's Syncera offering.
A pair of high-volume orthopedists who specialize in hip and knee replacement surgeries are skeptical of generic or "repless" sales models, in which medical device companies offer lower-cost implants without a sales rep on hand to advise during the procedure.
Royal Oak Medical Devices touts its 'repless' generic sales model, saying it can save its hospital customers more than $100,000 a year on their orthopedic implant spends.
Royal Oak Medical Devices says it can save its hospital customers more than $100,000 a year on their orthopedic implant spends, using its so-called 'repless' generic sales model.
Here's a look at some of the top regulatory stories for medical device companies this week: Regulators deal Wright Medical a double whammy; Medtronic wins FDA approval for Melody pulmonary valve; FDA approves Cohera's TissuGlu surgical sealant; FDA approves Medtronic's Pipeline Flex aneurysm device; Sorin wins MRI-safe pacemaker approval in Japan
Wright Medical plans to float $400 million worth of senior notes.
Wright Medical (NSDQ:WMGI) said today that it plans to float $400 million worth of senior debt it plans to hedge with cash convertible note hedge deals with institutional investors.
U.S. anti-trust and safety regulators ask Wright Medical for more information on its pending merger with Tornier and flag the 3rd-party vendor's plant where its Augment bone putty is made; post-merger management roster is revealed.
Stryker CEO Kevin Lobo says he doesn't view the so-called 'repless' generic sales models piloted by orthopedic rivals Smith & Nephew and Wright Medical as a serious threat.